Investor Presentation Q1-Q3 2020
39
Investor presentation
First nine months of 2020
The total branded diabetes market for the first half of 2020,
annualised, had a global value of DKK ~300 billion
DKK
billion
350
+5%
295
300
276
250
Global diabetes market
DKK
The USA
-1%
billion
150
143 145
2018/19
2019/20
-13%
100
+21%
Growth at CER
61
54
54
-13%
43
50
23 21
+3%
15 16
0
200
Total
Insulin
GLP-1
DPP-IV
SGLT-2
-3%
DKK
Rest of world
150
+12%
130 128
billion
150
24%
150
134
100
-2%
+6%
73
58
60 60
19%
100
69 73
+4%
+33%
50
34
28
50
37 39
14 19
0
Total
0
Insulin
GLP-1
DPP-IV
SGLT-2
SGLT-2
2018/19: Covers the four quarters from Q3 2018 to Q2 2019, except for Boehringer Ingelheim share of Trajenta which covers full year; 20182019/20: Covers the four quarters from Q3 2019 to Q2 2020, except for Boehringer Ingelheim share of Trajenta which
covers full year 2019; Note: Constant exchange rates between periods and Boehringer Ingelheim's regional split is based on regional split from 2019 Annual report for prescription medicine; Source: Company reported sales
Total
Insulin
GLP-1
+37%
13 18
DPP-IV
Novo NordiskⓇView entire presentation